Quick Dispatch:
Your summit study tirzepatide Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your summit study tirzepatide Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity ships.
Need Help?
Questions about summit study tirzepatide Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for summit study tirzepatide Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity in your area.
Impact of Obesity Severity on the Effects of Tirzepatide in HFpEF: The SUMMIT Trial
29.10
Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity
29.62
Tirzepatide Improves HFpEF Symptoms and Outcomes
26.45
SURMOUNT-1 Trial
27.97
American Heart Association Scientific Sessions 2024 has started off with a bang! Results are in for the SUMMIT study: Treatment with Tirzepatide (Mounjaro/ Zepbound) was associated with 38% ⬇️ in combined risk
29.86
🔴Another GLP-1 drug success. Tirzepatide in heart failure with preserved ejection fraction (HFpEF) with longer term follow-up than 2 previous trials with semaglutide ⤵️ #AHA24 🔹In patients with heart failure with preserved
20.04
AHA 24 Late-Breaking Discussion: SUMMIT: Tirzepatide in Patients with HFpEF and Obesity
28.96
